BRCA2 and pancreatic neoplasm: Pancreatic cancer cells, such as Capan carrying a BRCA2 mutation and initially sensitive to PARP inhibitors, and the C2-2 clone derived from Capan and exhibiting resistance to PARP inhibitors, have been instrumental in studying PARP inhibitor resistance [33].